INmune Bio Receives EMA’s Authorization in France and Spain for Phase II Clinical Trial of XPro(TM) for Early Alzheimer’s Disease
November 27, 2023
Adial Announces $5,000,000 Above Market Private Placement at $3.00 Per Share
July 7, 2021
Related Post
-
-
Silo Pharma Enters into Exclusive License Agreement with Medspray Pharma BV for Intranasal Technology used in SPC-15 Treatment for PTSD
November 21, 2023
-
INmune Bio Inc. Announces Expansion of Phase II Clinical Trial for Alzheimer’s Disease in Europe
November 15, 2023
-
Palatin Reports First Quarter Fiscal Year 2024 Financial Results and Provides Corporate Update
November 14, 2023